Research analysts at Numis Securities Ltd assumed coverage on shares of Allergy Therapeutics plc (LON:AGY) in a research note issued to investors on Wednesday. The firm set a “buy” rating and a GBX 37 ($0.48) price target on the stock. Numis Securities Ltd’s target price suggests a potential upside of 101.36% from the stock’s current price.

A number of other research firms also recently commented on AGY. Panmure Gordon reissued a “buy” rating and issued a GBX 53 ($0.69) price objective on shares of Allergy Therapeutics plc in a research note on Friday, June 10th. Stifel Nicolaus reissued a “buy” rating and issued a GBX 72 ($0.94) price objective on shares of Allergy Therapeutics plc in a research note on Friday, July 8th.

Allergy Therapeutics plc (LON:AGY) traded up 0.000% during trading on Wednesday, hitting GBX 18.375. The stock had a trading volume of 494,558 shares. The company has a 50 day moving average of GBX 18.81 and a 200-day moving average of GBX 22.76. Allergy Therapeutics plc has a 12-month low of GBX 18.00 and a 12-month high of GBX 34.82. The company’s market cap is GBX 102.81 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/allergy-therapeutics-plc-agy-receives-new-coverage-from-analysts-at-numis-securities-ltd.html

Allergy Therapeutics plc Company Profile

Allergy Therapeutics Plc is a United Kingdom-based pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum free products. It provides information to healthcare professionals about the prevention, diagnosis and treatment of allergic conditions with focus on allergy vaccination, which is also known as specific immunotherapy or desensitization therapy.

Receive News & Ratings for Allergy Therapeutics plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics plc and related companies with MarketBeat.com's FREE daily email newsletter.